Methods for diagnosing, prognosing, and treating colorectal cancer using biomarker expression

Patent metadata

Field	Value
Publication number	US-11618926-B2
Application number	US-201816489597-A
Country	US
Kind code	B2
Filing date	Feb 28, 2018
Priority date	Feb 28, 2017
Publication date	Apr 4, 2023
Grant date	Apr 4, 2023

Abstract

Dysregulated expression of microRNAs (miRNAs) has emerged as a hallmark feature in human cancers. Aspects of the disclosure relate to methods for selecting optimal therapy for a patient from several alternative treatment options. A major clinical challenge in cancer treatment is to identify the subset of patients who will benefit from a therapeutic regimen, both in metastatic and adjuvant settings. The number of anti-cancer drugs and multi-drug combinations has increased substantially in the past decade, however, treatments continue to be applied empirically using a trial-and-error approach. Here methods and compositions are provided to determine the optimal treatment option for cancer patients.

First claim

What is claimed is:

1. A method for treating a patient having colorectal cancer comprising: administering adjuvant therapy to the patient; wherein the patient was determined to have an increased expression level of miR-32, miR-181b-1, miR-188, miR-193b, miR-195, miR-424, miR-425, miR-592, miR-3677, and miR-4326 in a colorectal cancer biopsy sample; wherein the expression is increased in comparison to the expression levels of the same miRNAs in colorectal cancer tissue samples obtained from patients without lymph node metastasis.

2. The method of claim 1 , wherein the method further comprises measuring expression levels of the miRNAs in the colorectal cancer biopsy sample.

3. The method of claim 2 , wherein the method further comprises comparing the expression levels of the miRNAs in the colorectal cancer biopsy sample to the expression levels of the same miRNAs in colorectal cancer tissue samples obtained from patients without lymph node metastasis.

4. The method of claim 2 , wherein the method further comprises calculating a risk score based on the expression levels of the miRNAs in the colorectal cancer biopsy sample.

5. The method of claim 4 , wherein the risk score is compared to a cut-off value.

6. The method of claim 1 , wherein the patient has Stage I, II, III, or IV colorectal cancer.

7. The method of claim 1 , wherein the expression levels are normalized.

8. The method of claim 1 , wherein the adjuvant therapy comprises cetuximab, 5-fluorouracil, oxaliplatin, irinotecan, bevacizumab, panitumumab, afibercept, leucovorin, and/or radiotherapy.

9. The method of claim 1 , wherein the method further comprises surgical resection of a primary tumor or metastatic tumor.

10. The method of claim 1 , wherein the patient was determined to have one or more risk factors selected from poorly differentiated tissues, increased tumor depth; lymphatic invasion, and venous invasion.

Assignees

• Baylor Res Institute

Inventors

• Goel Ajay
• Kandimalla Raju
• Toden Shusuke
• Roy Roshni
• Ozawa Tsuyoshi
• Matsuyama Takatoshi
• Weng Wenhao

Classifications

• C12Q2600/158

  Expression markers · CPC title

• C12Q1/68

  involving nucleic acids · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/178

  miRNA, siRNA or ncRNA · CPC title

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title